Analyst Price Targets — AMGN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 13, 2026 4:30 pm | — | UBS | $420.00 | $358.68 | TheFly | Amgen price target raised to $420 from $400 at UBS |
| July 13, 2026 10:51 am | — | Guggenheim | $343.00 | $363.39 | StreetInsider | Amgen (AMGN) PT Raised to $343 at GuggenheimMember Login |
| July 8, 2026 11:36 am | — | Morgan Stanley | $333.00 | $368.10 | TheFly | Amgen price target lowered to $333 from $340 at Morgan Stanley |
| July 1, 2026 12:48 pm | Evan David Seigerman | BMO Capital | $400.00 | $362.45 | StreetInsider | BMO Capital Reiterates Outperform Rating on Amgen (AMGN) |
| June 16, 2026 10:40 am | Salim Syed | Mizuho Securities | $303.00 | $350.53 | StreetInsider | Amgen (AMGN) PT Raised to $303 at Mizuho |
| June 9, 2026 8:37 pm | — | Morgan Stanley | $340.00 | $344.57 | StreetInsider | Amgen (AMGN) PT Raised to $340 at Morgan StanleyMember Login |
| June 5, 2026 12:52 pm | — | Goldman Sachs | $389.00 | $352.62 | TheFly | Amgen price target lowered to $389 from $425 at Goldman Sachs |
| May 14, 2026 10:58 am | — | Piper Sandler | $427.00 | $336.45 | TheFly | Amgen price target lowered to $427 from $432 at Piper Sandler |
| May 4, 2026 11:22 am | — | Guggenheim | $340.00 | $329.82 | TheFly | Amgen price target lowered to $340 from $351 at Guggenheim |
| May 1, 2026 1:31 pm | — | Morgan Stanley | $332.00 | $329.31 | TheFly | Amgen price target raised to $332 from $326 at Morgan Stanley |
Latest News for AMGN
The FDA's approval of Merck (NYSE:MRK | MRK Price Prediction) enlicitide decanoate, marketed as Lipfendra, marks the first once-daily oral PCSK9 inhibitor cleared for adults with high LDL cholesterol, including heterozygous familial hypercholesterolemia.
Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Amgen (AMGN) closed the most recent trading day at $355.25, moving 1.44% from the previous trading session.
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Harmony Biosciences Holdings, Inc. (HRMY) and Amgen (AMGN). But which of these two companies is the best option for those looking for undervalued stocks?
Pfizer (NYSE: PFE | PFE Price Prediction) and Amgen (NASDAQ: AMGN) both reported Q1 2026 results this quarter, and the numbers reveal two very different bets on the future of oncology.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.